285 related articles for article (PubMed ID: 28804110)
1. [Current and future prospects of nuclear medicine in dementia].
Ito K; Inui Y; Kizawa T; Kimura Y; Kato T
Rinsho Shinkeigaku; 2017 Sep; 57(9):479-484. PubMed ID: 28804110
[TBL] [Abstract][Full Text] [Related]
2. Nuclear medicine diagnostic techniques in the era of pathophysiology-based CSF biomarkers for Alzheimer's disease.
Weih M; Degirmenci U; Kreil S; Suttner G; Schmidt D; Kornhuber J; Lewczuk P; Kuwert T
J Alzheimers Dis; 2011; 26 Suppl 3():97-103. PubMed ID: 21971454
[TBL] [Abstract][Full Text] [Related]
3. SPECT and PET imaging in Alzheimer's disease.
Valotassiou V; Malamitsi J; Papatriantafyllou J; Dardiotis E; Tsougos I; Psimadas D; Alexiou S; Hadjigeorgiou G; Georgoulias P
Ann Nucl Med; 2018 Nov; 32(9):583-593. PubMed ID: 30128693
[TBL] [Abstract][Full Text] [Related]
4. Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus.
Arbizu J; García-Ribas G; Carrió I; Garrastachu P; Martínez-Lage P; Molinuevo JL
Rev Esp Med Nucl Imagen Mol; 2015; 34(5):303-13. PubMed ID: 26099942
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic.
Morinaga A; Ono K; Ikeda T; Ikeda Y; Shima K; Noguchi-Shinohara M; Samuraki M; Yanase D; Yoshita M; Iwasa K; Mastunari I; Yamada M
Dement Geriatr Cogn Disord; 2010; 30(4):285-92. PubMed ID: 20861634
[TBL] [Abstract][Full Text] [Related]
6. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.
Mosconi L
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):486-510. PubMed ID: 15747152
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography imaging in dementia.
Herholz K; Carter SF; Jones M
Br J Radiol; 2007 Dec; 80 Spec No 2():S160-7. PubMed ID: 18445746
[TBL] [Abstract][Full Text] [Related]
8. Guidance for reading FDG PET scans in dementia patients.
Herholz K
Q J Nucl Med Mol Imaging; 2014 Dec; 58(4):332-43. PubMed ID: 25391316
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic value of FDG and amyloid PET in Alzheimer's disease-A systematic review.
Rice L; Bisdas S
Eur J Radiol; 2017 Sep; 94():16-24. PubMed ID: 28941755
[TBL] [Abstract][Full Text] [Related]
10. Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting.
Perani D; Cerami C; Caminiti SP; Santangelo R; Coppi E; Ferrari L; Pinto P; Passerini G; Falini A; Iannaccone S; Cappa SF; Comi G; Gianolli L; Magnani G
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):499-508. PubMed ID: 26341365
[TBL] [Abstract][Full Text] [Related]
11. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain
Nobili F; Arbizu J; Bouwman F; Drzezga A; Agosta F; Nestor P; Walker Z; Boccardi M;
Eur J Neurol; 2018 Oct; 25(10):1201-1217. PubMed ID: 29932266
[TBL] [Abstract][Full Text] [Related]
12. Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia.
Cerami C; Della Rosa PA; Magnani G; Santangelo R; Marcone A; Cappa SF; Perani D
Neuroimage Clin; 2015; 7():187-94. PubMed ID: 25610780
[TBL] [Abstract][Full Text] [Related]
13. Concordance between (99m)Tc-ECD SPECT and 18F-FDG PET interpretations in patients with cognitive disorders diagnosed according to NIA-AA criteria.
Ito K; Shimano Y; Imabayashi E; Nakata Y; Omachi Y; Sato N; Arima K; Matsuda H
Int J Geriatr Psychiatry; 2014 Oct; 29(10):1079-86. PubMed ID: 24687634
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's Disease FDG PET Imaging Pattern in an Amyloid-Negative Mild Cognitive Impairment Subject.
Tiepolt S; Patt M; Hoffmann KT; Schroeter ML; Sabri O; Barthel H
J Alzheimers Dis; 2015; 47(3):539-43. PubMed ID: 26401690
[TBL] [Abstract][Full Text] [Related]
15. Impact of molecular imaging on the diagnostic process in a memory clinic.
Ossenkoppele R; Prins ND; Pijnenburg YA; Lemstra AW; van der Flier WM; Adriaanse SF; Windhorst AD; Handels RL; Wolfs CA; Aalten P; Verhey FR; Verbeek MM; van Buchem MA; Hoekstra OS; Lammertsma AA; Scheltens P; van Berckel BN
Alzheimers Dement; 2013 Jul; 9(4):414-21. PubMed ID: 23164552
[TBL] [Abstract][Full Text] [Related]
16. Multiscale deep neural network based analysis of FDG-PET images for the early diagnosis of Alzheimer's disease.
Lu D; Popuri K; Ding GW; Balachandar R; Beg MF;
Med Image Anal; 2018 May; 46():26-34. PubMed ID: 29502031
[TBL] [Abstract][Full Text] [Related]
17. [Positron emission tomography: contribution to diagnosis of dementia and development of disease-modifying drugs].
Ito K; Kato T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2009 Aug; 29(4):153-60. PubMed ID: 19764482
[TBL] [Abstract][Full Text] [Related]
18. Impact of (18)FDG PET and (11)C-PIB PET brain imaging on the diagnosis of Alzheimer's disease and other dementias in a regional memory clinic in Hong Kong.
Shea YF; Ha J; Lee SC; Chu LW
Hong Kong Med J; 2016 Aug; 22(4):327-33. PubMed ID: 27313272
[TBL] [Abstract][Full Text] [Related]
19. [Molecular neuroimaging in the study of cognitive impairment: contribution of the cerebral blood flow SPECT with 99mTc-HMPAO and 18F-FDG PET/CT scan].
Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla J; Portilla-Quattrociocchi H; Medina-Quiroz P; Ortega F; Rodríguez E; Mateo I; Vázquez-Higuera JL; de Arcocha M; Carril JM
Rev Esp Med Nucl; 2011; 30(5):301-6. PubMed ID: 21640440
[TBL] [Abstract][Full Text] [Related]
20. FDG-PET for Prediction of AD Dementia in Mild Cognitive Impairment. A Review of the State of the Art with Particular Emphasis on the Comparison with Other Neuroimaging Modalities (MRI and Perfusion SPECT).
Sanchez-Catasus CA; Stormezand GN; van Laar PJ; De Deyn PP; Sanchez MA; Dierckx RA
Curr Alzheimer Res; 2017; 14(2):127-142. PubMed ID: 27357645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
